Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Get Free Report) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totaling 6,068 shares, a drop of 38.6% from the April 30th total of 9,883 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,229 shares, the days-to-cover ratio is presently 1.2 days.
Institutional Investors Weigh In On Molecular Partners
A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Molecular Partners in a research report on Wednesday, April 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, April 10th. Finally, TD Cowen reiterated a “buy” rating on shares of Molecular Partners in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.38.
Molecular Partners Stock Down 3.7%
Molecular Partners stock traded down $0.15 during trading hours on Thursday, hitting $3.88. The stock had a trading volume of 1,082 shares, compared to its average volume of 4,621. The business’s 50 day simple moving average is $4.13 and its 200-day simple moving average is $4.32. Molecular Partners has a one year low of $3.41 and a one year high of $5.36. The stock has a market cap of $156.76 million, a price-to-earnings ratio of -2.00 and a beta of 1.07.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). Research analysts anticipate that Molecular Partners will post -1.4 EPS for the current fiscal year.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.
See Also
- Five stocks we like better than Molecular Partners
- The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
- Gen Z Trends Make These 3 Stocks Worth Watching
- How the Memory Shortage Is Crushing the Gaming Industry
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
